While melanoma is one of the most aggressive cancers, making early detection crucial for outcomes, because it is visible on the surface, there are opportunities to catch it early, said Sancy Leachman, MD, PhD, professor and chair in the Department of Dermatology and director of the Melanoma Research Program at the Knight Cancer Institute at Oregon Health and Science University.
This content was produced independently by The American Journal of Managed Care® and is not endorsed by the American Academy of Dermatology.
While melanoma is one of the most aggressive cancers, making early detection crucial for outcomes, because it is visible on the surface, there are opportunities to catch it early, said Sancy Leachman, MD, PhD, professor and chair in the Department of Dermatology and director of the Melanoma Research Program at the Knight Cancer Institute at Oregon Health and Science University.
Leachman presented on an early detection program in Oregon, as well as germline genetic testing for patients at risk of developing melanoma, at the annual meeting of the American Academy of Dermatology.
Transcript
Melanoma is a particularly aggressive cancer that spreads fast. Can you explain the importance of early detection?
There are a couple of features about melanoma that make it really sort of the poster child of early detection, if you want to call it that. First of all, it's on the skin surface—the vast, vast majority of melanomas you can see with your own eyes, you can tell that it's there. And so, if you're paying attention, it's an opportunity for early detection. It's not like a cancer that's on the inside where you can't really see it, and you would never know it's there. With melanoma, if you're paying attention, you got a chance to catch it.
The question is then, are you going to catch it early enough? And the problem with melanoma, is it's probably one of the most aggressive cancers in man, if you think about how soon something starts to metastasize to the rest of your body. Melanoma will start to metastasize when it's only a millimeter thick. In comparison, if you look at the data, for example, and compare between melanoma and breast cancer survival rates: the 5-year survival rates for melanoma at 1 millimeter, are about the same as the survival rates for breast cancer at 2 centimeters.
You really do need to catch it early, but because it's on the surface of the skin, you can see it—you can usually see it—to be able to do that if you're paying attention. So, there’s an opportunity for education.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Rare Autoimmune Disorder Linked With Increased Risk of Certain Skin Cancers
April 21st 2025The risk of some skin cancers, including squamous cell carcinoma, basal cell carcinoma, and non-melanoma skin cancer, was particularly heightened among patients with severe mucous membrane pemphigoid.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More